Full Circle PGx LLC can partner with you to optimize the medication for your patients.
There is a rapidly-growing body of robust literature supporting the implementation of PGx into clinical practice. The Clinical Pharmacogenetics Implementation Consortium (CPIC) produces guidelines that are peer-reviewed, regularly updated, and freely available (see link below) to guide drug therapy with certain gene-drug pairs in the presence of certain genetic variants.
Many of these gene-drug pairs and genetic variants are well-studied, clinically significant and actionable in everyday medical practice.
| Neuro/Psychiatry Drugs Affected DNA Variations | Top 200 Drugs Dispensed 2022/2023 | Drug Class | Active Ingredient(s) | PharmGKB Evidence Level (Level 1A is the highest) |
|---|---|---|---|---|
| Lamictal | X | Anticonvulsant drug | Lamotrigine | Level 1A |
| Depakote | X | Anticonvulsant drug | Valproate sodium | Level 3 |
| Zyprexa | X | Antipsychotic drug | Olanzapine | Level 3 |
| Seroquel | X | Antipsychotic drug | Quetiapine | Level 1A |
| Risperdal | X | Antipsychotic drug | Risperidone | Level 1A |
| Xanax | X | Benzodiazepine | Alprazolam | Level 5 |
| Valium | X | Benzodiazepine | Diazepam | Level 3 |
| Ativan | X | Benzodiazepine | Lorazepam | Level 3 |
| Concerta | X | CNS Stimulant | Methylphenidate | Level 3 |
| Strattera | X | Norepinephrine reuptake inhibitor | Atomoxetine | Level 1A |
| Effexor | X | SNRI | Venlafaxine | Level 1A |
| Celexa | X | SSRI | Citalopram | Level 1A |
| Lexapro | X | SSRI | Escitalopram | Level 1A |
| Prozac | X | SSRI | Fluoxetine | Level 3 |
| Paxil | X | SSRI | Paroxetine | Level 1A |
| ZOLOFT | X | SSRI | Sertraline | Level 1A |
| Wellbutrin | Antidepressant/Smoke cessation | Bupropion | Level 2 | |
| Cymbalta | Antidepressant/nerve pain | duloxetine | Level 3 | |
| Ritalin | CNS Stimulant | methylphenidate | Level 3 | |
| Remeron | Antidepressant | mirtazapine | Level 2 | |
| Trintellix | Antidepressant | vortioxetine | Level 1A |
| Cardiovascular drugs Affected DNA Variations | Top 200 drugs Dispensed 2022/2023 | Drug Class | Active Ingredient(s) | PharmGKB Evidence Level (Level 1A is the highest) |
|---|---|---|---|---|
| Eliquis | X | Anticoagulant | Apixaban | Level 3 |
| Coumadin | X | Anticoagulant drug | Warfarin | Level 1A |
| Pradaxa | X | Anticoagulant drug | Dabigatran | Level 3 |
| Xarelto | X | Anticoagulant drug | Rivaroxaban | Level 3 |
| Plavix | X | Antiplatelet drug | Clopidogrel | Level 1A |
| Zebeta | X | Beta-blocker | Bisoprolol | Level 3 |
| Coreg | X | Beta-blocker | Carvedilol | Level 3 |
| Lopressor | X | Beta-blocker | Metoprolol | Level 1A |
| Lipitor | X | Statin | Atorvastatin | Level 1A |
| Pravachol | X | Statin | Pravastatin | Level 1A |
| Crestor | X | Statin | Rosuvastatin | Level 1A |
| Zocor | X | Statin | Simvastatin | Level 1A |
| Mevacor | X | Statin | Lovastatin | Level 1A |
| Benicar | X | Thiazide diuretic /Angiotensin II blocker | Hydrochlorothiazide / Olmesartan | Level 2 |
| Demadex | Diuretic | Torsemide | Level 3 | |
| Atacand | Antihypertensive | Candesartan | Level 3 | |
| Avapro | Antihypertensive | Irbesartan | Level 3 | |
| Micardis | Antihypertensive | Telmisartan | Level 3 | |
| Cozaar/Hyzaar | Antihypertensive | Losartan | Level 3 | |
| Brilinta | Antiplatelet drug | Ticagrelor | Level 3 |
| Gastrointestinal Drugs Affected by DNA Variations | Top 200 Precribed Drugs | Drug Class | Active Ingredient | PharmGKB Evidence Level (Level 1A is the highest) |
|---|---|---|---|---|
| Zofran | X | Antiemetic drug | Ondansetron | Level 1A |
| Kapidex, Dexilant | Angiotensin II Receptor Blockers (ARBs) | dexlansoprazole | Level 1A | |
| Nexium | X | Proton-pump inhibitor | esomeprazole/omeprazole | Level 1A |
| Prevacid | X | Proton-pump inhibitor | Lansoprazole | Level 1A |
| Protonix | X | Proton-pump inhibitor | Pantoprazole | Level 1A |
| Azulfidine, Salazopyrin, Sulazine | Sulfonamides | Sulfasalazine | Level 3 |
| Pain Management drugs Affected DNA Variations | Top 200 Precribed Drugs | Drug Class | Active Ingredient | PharmGKB Evidence Level (Level 1A is the highest) |
|---|---|---|---|---|
| Oxycodone | Opioid | Oxycodone | Level 2 | |
| Hydrocodone | X | Antihistamine Narcotic | Chlorpheniramine/Hydrocodone | Level 1A |
| Diclofenac | X | NSAID | Diclofenac | Level 3 |
| Ibuprofen | X | NSAID | Ibuprofen | Level 1A |
| Naproxen | NSAID | Naproxen | Level 3 | |
| Ultram | X | Opiate narcotic | Tramadol | Level 1A |
| Methadone | X | Opioid analgesic | Methadone | Level 2 |
| Fentanyl | X | Opioid narcotic | Fentanyl | Level 2 |
| Codeine/Tylenol #3 | Narcotic | codeine | Level 1A | |
| Morphine | Narcotic | morphine | Level 3 |
| Oncology drugs Affected DNA Variations | Top 200 drugs Dispensed 2022/2023 | Drug Class | Active Ingredient(s) | PharmGKB Evidence Level (Level 1A is the highest) |
|---|---|---|---|---|
| Zofran | X | Antiemetic drug | Ondansetron | Level 1A |
| Fluorouracil (5-fu) | Chemotherapy | Fluorouracil | Level 1A | |
| Xeloda | Chemotherapy | Capecitabine | Level 1A | |
| Mercaptopurine | Chemotherapy | Mercaptopurine | Level 1A | |
| Thioguanine | Chemotherapy | thioguanine | Level 3 | |
| Camptosar | Chemotherapy | Irinotecan | Level 1A | |
| Iressa | Chemotherapy | Gefitinib | Level 1A | |
| Tamoxifen | Estrogen Modulator | Tamoxifen | Level 1A | |
| Cisplatin | Chemotherapy | Cisplatin | Level 3 |